Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Explores MicroRNA Signatures to Detect and Classify Several Prominent Cancers

By LabMedica International staff writers
Posted on 02 Aug 2023

Cancer remains one of the world's most devastating diseases. More...

As the medical community strives to enhance diagnostic tools, microRNAs, or miRNAs, have taken center stage in biomedical research. These small non-coding ribonucleic acids (RNAs) play a crucial role in all biological functions, primarily gene regulation. Consequently, miRNAs oversee various biological and pathological processes, including cancer formation and progression. The close link between miRNAs and many cancers has led to an increased interest in using miRNA expression profiling data for non-invasive early detection. Machine learning has proven to be instrumental in creating high-performance pan-cancer classification models and identifying potential novel miRNA biomarkers for clinical investigation. However, it's crucial to understand how these data science methodologies relate to known biological processes to better integrate them into clinical settings.

Researchers from Florida Atlantic University (FAU, Boca Raton, FL, USA) further investigated the potential of miRNAs as biomarkers for cancer classification and enhancing clinical classification applications. They have developed a multiclass cancer diagnostic model using miRNA expression profiles through an iterative process that applied multiple techniques to an expanding dataset of miRNA expression quantification data. The study involved assessing how top miRNA features selected by machine learning models correlate with clinically and biologically verified miRNA biomarkers. Using Support Vector Machine and Random Forest machine learning models, they developed cancer classification models and progressively added more cancer classes to the multiclass models. The study analyzed the relationship between relevant miRNAs identified through feature selection and the classification models' performance metrics across 20 iterations, each incorporating another primary sample site, thereby increasing the types of cancer included.

The researchers studied the changes in success metrics as more cancer types were added, how the 20-miRNA signature evolved with the inclusion of more cancer types, and the overall characteristics of the full dataset using principal component analysis, a well-established technique for analyzing large datasets with numerous dimensions or features. This study differs from earlier ones focusing on miRNA feature signatures for a final multiclass dataset as it tracked changes in clinical and biological relevance with each addition of a cancerous tissue type. The study's findings suggest that models with more cancer classes shift toward focusing on cancer-diverse miRNAs of greater relevance with characterized functionality. The study implies that miRNAs might be highly unique to particular cancerous tissues and could serve as strong biomarkers for detection and classification. However, the study noted that the current verified biomarkers fall toward more cancer-wide miRNAs when detecting cancer.

The study offers insights into possible relationships between the overall clinical relevance of the feature extraction signature and the models' success metrics. It demonstrates the feasibility of using a multi-tissue miRNA cancer signature as a generalizable signature for single-class cancer detection in various prevalent cancers. The findings revealed that although the performance metrics decreased as the number of cancer classes increased, the percentage relevance of the miRNA feature selection signature increased marginally before stabilizing. Also, after performing principal component analysis, non-cancer tissues from all samples showed very similar expression visualizations, whereas all cancerous tissues had unique profiles.

“MicroRNAs have significant promise for future diagnostic tests because they can be detected directly from biological fluids such as blood, urine or saliva as well as the availability of high-quality measurement techniques for miRNAs,” said Oneeb Rehman, corresponding author and a Ph.D. candidate in the Department of Electrical Engineering and Computer Science within FAU’s College of Engineering and Computer Science. “This makes understanding and characterizing the biological basis behind potential miRNA classification tools crucial for integration into clinical environments.”

Related Links:
FAU


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: Melioidosis is a serious, sometimes fatal infection caused by Burkholderia pseudomallei, a bacterium found in tropical and subtropical soil and surface water. (Image Credit: Adobe Stock)

Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions

Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: Siemens Healthineers has begun carving out its in vitro diagnostics business as a standalone company named Olyrian Diagnostics (Photo courtesy of Siemens Healthineers)

Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business

Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.